Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs BIOAF

Healthcare Biotechnology
Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


GREY:BIOAF - Post by User

biOasis Technologies Ord Shs > This is why i love this board
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(192)
•••
Comment by craighenryon Jan 23, 2023 10:46pm
79 Views
Post# 35241405

RE:RE:RE:RE:RE:RE:RE:This is why i love this board

RE:RE:RE:RE:RE:RE:RE:This is why i love this board
unclepieman wrote:

Here is your evidence: Bti sitting at 4 cents usd after almost 15y journey of no actual partnerships or milestones achieved that teiggered any actual payments... and oh ya, no one is interested in even buying us at a dumpster sale prices... and oh the companies leaders have all given up... all of which for 13 of these years i've been a bag holder for.

what evidence do you have that x3 actually works? FDA approval? Drug pipeline? Milestone payments that insinuate partner confidence? Management deeply invested with their own $? 


What!?




He knows unclepieman because only HE can "read between the lines"

JBroke knows the science!!

He reads scientific papers for hours on end!!!


He knows so much more than Scientists with PHDs and Masters.



<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities